Study represents continued efforts to further understand the clinical and pharmacological potential of 5-MeO-DMT BPL-003 is Beckley Psytech’s innovative dry powder intranasal formulation of 5-MeO-DMT using FDA approved intranasal delivery devices Data from Phase 1 will be used to select lead compound for upcoming Phase 2 in treatment resistant depression (TRD) April 05, 2022 02:00 AM Eastern…


Previous articlePT307 – Kathryn L. Tucker, JD – The Right to Try Act and the Battle for Psilocybin Access
Next articlePsychedelic Bulletin: Homecoming Raises $4m Seed; Angermayer Increases atai Stake by 1m Shares; 6 Projects Readers are Working On